1. Comparison of Intralesional Hyaluronic Acid vs . Verapamil for the Treatment of Acute Phase Peyronie’s Disease: A Prospective, Open-Label Non-Randomized Clinical Study
- Author
-
Andrea Cocci, Fabrizio Di Maida, Gianmartin Cito, Pierangelo Verrienti, Nicola Laruccia, Riccardo Campi, Andrea Mari, Marina Di Mauro, Marco Falcone, Giovanni E. Cacciamani, Giulio Garaffa, Andrea Minervini, and Giorgio Ivan Russo
- Subjects
hyaluronic acid ,penile curvature ,penile induration ,peyronie disease ,verapamil ,Medicine ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Purpose: To compare the efficacy and safety of intralesional hyaluronic acid (HA) as compared with verapamil injection in patients with Peyronie’s disease (PD). Materials and Methods: Between January 2015 and December 2018, men in PD acute phase were prospectively recruited. This open-label, prospective study included 2 different protocols. Group A: 8-week cycle of weekly intraplaque injections with HA; Group B: 8-week cycle of weekly intraplaque injections with verapamil. Penile curvature, plaque size, International Index of Erectile Function (IIEF)-15 score and visual analogue scale (VAS) were assessed at baseline and after 3 months. Results: Two-hundred forty-four patients were enrolled. Of these, 125 received intralesional HA (Group A), 119 received intralesional verapamil (Group B). At enrollment, median age was 56.0 years (interquartile range [IQR]=47.0–63.0 years), median curvature 35.0° (IQR=25.0°–45.0°), median IIEF-15 score 19.0 (IQR=16.0–23.0), median VAS 4.0 (IQR=4.0–5.0). Median difference for IIEF-15 was 1.0 (95% confidence interval [CI]=1.12–1.94) in Group A and 0.0 (95% CI=-0.04–0.14) in Group B (p
- Published
- 2021
- Full Text
- View/download PDF